메디채널

주메뉴 바로가기
본문 바로가기

기상청 제공

닫기

라이프

AI and Multi-omics are Transforming Cancer Care: APAC Precision Oncology Conference Outlines the Future of Early Detection and Personalized Treatment

HONG KONG, Nov. 17, 2025 -- The APAC Precision Oncology Conference 2025, themed Artificial Intelligence (AI) & Multi-omics in Cancer Management, convened in Hong Kong on November 1, marking Lung Cancer Awareness Month with a clear message: AI and multi-omics are no longer theoretical - they are driving real-world advancements in cancer care across the Asia-Pacific (APAC) region. Co-organized by the Hong Kong Precision Oncology Society, The Hong Kong Polytechnic University, the Hong Kong Integrated Oncology Centre, the Artificial Intelligence Association of Hong Kong, and supported
- 김갑성 기자
- 2025-11-17 13:45
Akeso's Bispecific Antibody Targeting Aβ and BBB-Expressed Receptor Approved for Alzheimer's Disease Clinical Trials in China

HONG KONG, Nov. 17, 2025 -- Akeso, Inc. (HKEX: 9926.HK) announced that its AK152, a novel bispecific antibody targeting both amyloid-beta (Aβ) and blood-brain barrier (BBB) expressed receptor, has been granted approval by the National Medical Products Administration (NMPA) to initiate clinical trials for Alzheimer's Disease. AK152 is the first bispecific antibody developed in China for disease-modifying therapy in Alzheimer's Disease, marking a significant breakthrough in the field. Furthermore, it is Akeso's first innovative therapeutic candidate designed to target the central nervous
- 김갑성 기자
- 2025-11-17 10:29
WellsCare Partners with SolnanoMed to Launch IASO and IASO Ultra in Thailand

[ 메디채널 김갑성 기자 ] Partnership to Bring Innovative Wearable Cold-Laser Therapy to One of Southeast Asia's Fastest-Growing Healthcare Markets SEOUL, South Korea, Nov. 17, 2025 -- WellsCare Inc., a leading South Korean med-tech innovator in wearable cold-laser therapy, today announced that it has signed a supply agreement with SolnanoMed Co., Ltd., one of Thailand's most respected medical device distributors. The agreement follows WellsCare's recent FDA Thai approval for its flagship product, IASO Coldlaser — advanced photobiomodulation (PBM) therapy device designed for effective, drug-fr
- 김갑성 기자
- 2025-11-17 10:00
Fotona Appoints Aimee Desrosiers as Global Chief Marketing Officer

DALLAS, Nov. 16, 2025 -- Fotona, a global leader in high-performing laser systems and energy-based devices for aesthetic, dental and gynecological applications, today announces the appointment of Aimee Desrosiers as Global Chief Marketing Officer. In this role, Desrosiers will lead Fotona's global marketing organization, guiding brand strategy, digital transformation, and market expansion efforts across more than 70 countries worldwide. Desrosiers is a seasoned leader and marketer with experience partnering with high-growth organizations to accelerate brand and commerci
- 김갑성 기자
- 2025-11-16 18:12
테스칸, 펨토치즐 레이저 기술로 반도체 워크플로 확장

[ 메디채널 김갑성 기자 ] 브르노, 체코 2025년 11월 15일 -- 세계적인 전자현미경 제조기업 테스칸(Tescan)이 차세대 펨토초 레이저(femtosecond laser) 플랫폼 '펨토치즐(FemtoChisel)'을 통해 반도체 포트폴리오를 확장한다. 펨토치즐은 탁월한 속도, 정밀도, 재현성 및 품질로 반도체 샘플 준비 워크플로 향상에 기여할 수 있도록 설계됐다. 펨토치즐은 처리량과 적응성이 모두 중요한 반도체 연구•불량 분석 환경에 적합하도록 특별히 개발됐다. 나노미터 수준의 정밀도와 고처리량 지능형 레이저 가공 기술을 결합해 후속 FIB 연마 공정의 필요성을 획기적으로 줄이면서, 깨끗하고 손상 없는 표면을 제공한다. 이를 통해 현재와 미래 반도체 소재에 대한 연구와 불량 분석 속도를 크게 개선하는 효과를 낸다. 시린 아사프(Sirine Assaf) 테스칸 최고수익책임자(CRO)는 "반도체 연구•불량 분석 팀은 반도체 적층 구조 내 모든 소재 층에서 더 빠르고 신뢰할 수 있는 결과를 내달라는 압박을 지속적으로 받고 있다"면서 "우리는 펨토치즐을 통해 '반도체용 대규모 워크플로(
- 김갑성 기자
- 2025-11-15 23:44
MATELASER Launches W1 REGEN Series -- The World's Lightest Wearable Medical-Grade Cold Laser for Deep Tissue Healing

MIAMI, Fla., Nov. 15, 2025 -- MATELASER, INC., an FDA-certified U.S. manufacturer of therapeutic laser systems, today announced the crowdfunding debut of its W1 REGEN Series, including W1 REGEN and W1 REGEN ULTRA. Weighing only 24 grams per module, the W1 REGEN is the world's lightest wearable medical-grade cold laser — empowering anyone to experience deep-tissue recovery, pain relief, and enhanced circulation anytime, anywhere. Powered by patented VCSEL laser technology and dual wavelengths (660nm red + 810nm near-infrared), the W1 REGEN delivers up to 70mW laser output per mo
- 김갑성 기자
- 2025-11-15 00:00
Lundbeck files for marketing authorization across key Asian markets for Vyepti® (eptinezumab) for the preventive treatment of migraine

[ 메디채널 김갑성 기자 ] Lundbeck's new drug application (NDA) for Vyepti® (eptinezumab) accepted by Japan's Ministry of Health, Labor and Welfare (MHLW), marking a significant step forward towards expanding access to the novel preventive migraine treatment for patients across Japan Similar marketing authorization applications also accepted in China and South Korea, supported by Phase 3 SUNRISE trial data confirming the preventive efficacy of eptinezumab in Asian patients with migraine The submissions represent a milestone in Lundbeck's Focused Innovator strategy, extending operational capabi
- 김갑성 기자
- 2025-11-14 17:43
Tescan Expands Semiconductor Workflows with FemtoChisel Laser Technology

BRNO, Czech Republic, Nov. 14, 2025 -- Tescan expands its semiconductor portfolio with FemtoChisel, a next-generation femtosecond laser platform designed to enhance semiconductor sample preparation workflows with exceptional speed, precision, reproducibility, and quality. FemtoChisel was developed specifically for semiconductor research and failure analysis environments where both throughput and adaptability are critical. By combining nanometer-level precision and high-throughput intelligent laser processing, FemtoChisel delivers pristine surfaces while significantly reducing t
- 김갑성 기자
- 2025-11-14 17:07
PRISM BioLab Achieved Initial Milestone and Receives the Milestone Payment in Drug Discovery Collaboration with Ono Pharmaceutical Co., Ltd.

TOKYO, Nov. 14, 2025 -- PRISM BioLab, Co. Ltd. ("PRISM") announces that today, PRISM and Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka; President and COO: Toichi Takino; hereinafter "Ono") have achieved the initial milestone in the drug discovery collaboration and PRISM has confirmed receipt of the milestone payment. PRISM and Ono have entered into a "Joint Research and Licensing Agreement" on April 25, 2024, (hereinafter "the Agreement") for drug discovery in the oncology field. Under this Agreement, PRISM received an u
- 김갑성 기자
- 2025-11-14 16:00
Smartee Demonstrates World-Class Manufacturing Capacity to Support Global Growth

SHANGHAI, Nov. 14, 2025 -- Smartee Denti-Technology has showcased its world-class production system, designed to meet the increasing demand for its clear aligner products across the globe. With cutting-edge technology and robust manufacturing capabilities, Smartee supports its global brand expansion while serving orthodontic professionals in over 57 countries and regions. One of the key factors behind Smartee's success is its proprietary intelligent manufacturing system. Smartee launched China's first fully automated aligner production line in 2021, and with several years' cont
- 김갑성 기자
- 2025-11-14 14:44

이전

1 2 3 4 5 6 7 8 9 10

많이 본 기사

최근기사

2025-11-17_MON

발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.

UPDATE: 2025년 11월 17일 15시 20분